Pagari Life Science Corp. — SEC Form D Filing

Pagari Life Science Corp. filed an SEC Form D on May 12, 2026, reporting $97K raised in Pharmaceuticals.

Form D filing details

Filing
SEC Form D
Filing date
May 12, 2026
Amount reported
$97K
Round stage
Seed
Industry
Pharmaceuticals
Website
https://pagarilifescience.com/

What the company does

Securities: Equity. Exemption: Rule 506(b). Incorporated: DELAWARE

Problem

Conditions such as cold sores, genital herpes, shingles, burns, and post herpetic neuralgia often require treatments that are more effective, faster-acting, and less painful than current offerings.

Solution

The company is developing an advanced platform of anti-herpetic drugs aimed at providing faster healing, pain elimination, and safe, non-addictive treatments.

Why now

There is a growing need for effective, non-addictive treatments for herpetic conditions that do not rely on traditional medications.

Verdict

Investors said yes because the narrative of developing non-addictive, faster-acting herpetic treatments resonated with current healthcare trends, not because existing solutions were perceived as effective. They implicitly bet on the growing demand for safer therapeutic options amid rising concerns over addiction. However, the limited upside stems from a crowded pharmaceutical landscape where many companies are pursuing similar advancements, which may dilute differentiation and long-term market capture.

Source: SEC EDGAR Form D filing